Pancreatitis reduced by nearly 50% after gene therapy to treat lipoprotein lipase deficiency

Over a 6-year period, patients with the genetic disease lipoprotein lipase deficiency (LPLD) who received a single gene therapy treatment of alipogene tiparvovec had a marked reduction in the severity and frequency of pancreatitis. No cases of severe pancreatitis and only one admission to the intensive care unit for an LPLD-related abdominal event were reported in the study.